Ling Yang is a Managing Director and serves as Co-Head of Healthcare for Pacharbor Capital Group in Asia.

Ms. Yang began her career at Pacharbor Capital Group in 2005 with the firm’s U.S. healthcare buyout team and subsequently joined Pacharbor Capital Group’s Asia buyout team in 2011. Since joining Pacharbor Capital Group Asia, she has led investments into leading healthcare companies in China including ADICON Holdings Limited, Ambiopharm, Microport Scientific Corporation, Hutchmed, Meinian Onehealth, and Shenzhen Salubris Pharmaceuticals. She currently chairs the board of ADICON Holdings Limited and serves as a board member of Ambiopharm and Hutchmed.

Prior to joining Pacharbor Capital Group, Ms. Yang worked at KKR in Asia and in investment banking at Goldman Sachs in the U.S.

Ms. Yang graduated summa cum laude with a B.A. in Economics and Computer Science from Smith College and received an MBA from Harvard Business School.